TechMARK movers: Oxford profit-taking

19th Jan 2011 12:15

Scientific instruments supplier Oxford Instruments has been hit by profit-taking following its interim management statement. Trading has remained strong in the period since the 1 October. Orders, sales and profits are well ahead of the same period last year. The company has negotiated a new £50m bank facility, which will last for four years and can be extended to £70m. Shares in Oxford Instruments have trebled in the past year. GlaxoSmithKline has started a study that will test intravenous zanamivir as a treatment for influenza and compare it with Tamiflu. Glenmark has been given FDA approval to sell a generic version of malaria drug Malarone. Glenmark has to pay royalties to GlaxoSmithKline.FTSE TechMARK - Risers AEA Technology Group (AAT) 6.50p +9.24%Parity Group (PTY) 21.50p +4.88%ProStrakan Group (PSK) 106.75p +4.66%Asterand (ATD) 17.75p +4.41%RM (RM.) 165.00p +3.12%Vectura Group (VEC) 79.00p +1.94%Emblaze Ltd. (BLZ) 50.00p +1.52%Kewill (KWL) 89.00p +1.42%GlaxoSmithKline (GSK) 1,197.00p +1.31%Sinclair Pharma (SPH) 40.50p +1.25%Biocompatibles International (BII) 393.25p +1.22%FTSE TechMARK - Fallers Oxford Instruments (OXIG) 650.00p -5.32%Sepura (SEPU) 45.50p -5.21%Filtronic (FTC) 57.25p -2.97%Axis-Shield (ASD) 292.75p -2.50%ARM Holdings (ARM) 524.50p -2.24%Vislink (VLK) 23.00p -2.13%Optos (OPTS) 186.00p -2.11%BAE Systems (BA.) 354.00p -1.97%Renovo Group (RNVO) 77.75p -1.58%Ricardo (RCDO) 330.00p -1.49%